What is it about?
The immune checkpoint inhibitor exerts a therapeutic effect under the appropriate balance between the tumor immunogenecity and host immunity in patients with cancer. We have put forward a hypothesis regarding the desensitizing effect of cancer cachexia on PD-1/PD-L1 inhibitors in patients with advanced non-small-cell lung cancer.
Featured Image
Photo by AbsolutVision on Unsplash
Why is it important?
Cachectic patients exhibited a worse objective tumor response rate and progression free survival than non-cachectic patients even if they were potentially sensitive to PD-1/PD-L1 inhibitors with high PD-L1 expression on cancer cells.
Perspectives
Treatment strategies that combine anti-cachectic treatments and PD-1/PD-L1 inhibitors might attenuate the desensitizing effect of cancer cachexia and enhance efficacy of PD-1/PD-L1 inhibitors. We need further basic and clinical studies to test this hypothesis.
MD. PhD. Tateaki Naito
Shizuoka Cancer Center
Read the Original
This page is a summary of: Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer, JTO Clinical and Research Reports, March 2020, Elsevier,
DOI: 10.1016/j.jtocrr.2020.100020.
You can read the full text:
Contributors
The following have contributed to this page
